Elizabeth Tarka Biography and Net Worth

Insider of Idera Pharmaceuticals

Dr. Elizabeth Ann Tarka M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Prior to Complexa, Inc., Dr. Tarka served as Clinical Program Lead, Clinical Development at Janssen Pharmaceuticals, Inc. from September 2015 to September 2017, where she was the Clinical Program Leader for Xarelto® (rivaroxaban) and was responsible for the design, implementation and medical oversight for large multinational trials. Dr. Tarka held roles of increasing responsibility in late state clinical development of cardiovascular medications at GlaxoSmithKline from May 2003 to May 2015 and held the role of Senior Director, Clinical Development at the time of her transition to Janssen. Dr. Tarka earned her B.A. in Biochemistry and an M.D. from the University of Pennsylvania where she also completed her Internal Medicine residency and Cardiovascular fellowship training. She was also an Assistant Professor of Medicine in the Cardiovascular Division at the University of Pennsylvania where she had numerous major teaching and clinical responsibilities.

What is Elizabeth Ann Tarka's net worth?: The estimated net worth of Elizabeth Ann Tarka is at least $0.00 as of March 25th, 2021. Dr. Tarka owns 13,237 shares of Idera Pharmaceuticals stock worth more than $0 as of April 16th. This net worth estimate does not reflect any other investments that Dr. Tarka may own. Learn More about Elizabeth Ann Tarka's net worth.
How do I contact Elizabeth Ann Tarka?: The corporate mailing address for Dr. Tarka and other Idera Pharmaceuticals executives is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. Idera Pharmaceuticals can also be reached via phone at (484) 348-1600 and via email at [email protected]. Learn More on Elizabeth Ann Tarka's contact information.
Has Elizabeth Ann Tarka been buying or selling shares of Idera Pharmaceuticals?: Elizabeth Ann Tarka has not been actively trading shares of Idera Pharmaceuticals in the last ninety days. Most recently, Elizabeth Ann Tarka sold 5,018 shares of the business's stock in a transaction on Thursday, March 25th. The shares were sold at an average price of $1.35, for a transaction totalling $6,774.30. Following the completion of the sale, the insider now directly owns 13,237 shares of the company's stock, valued at $17,869.95. Learn More on Elizabeth Ann Tarka's trading history.
Who are Idera Pharmaceuticals' active insiders?: Idera Pharmaceuticals' insider roster includes John Kirby (CFO), Bryant Lim (SVP), Daniel Soland (COO), and Elizabeth Tarka (Insider). Learn More on Idera Pharmaceuticals' active insiders.

Elizabeth Ann Tarka Insider Trading History at Idera Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/25/2021	Sell	5,018	$1.35	$6,774.30	13,237
1/12/2021	Sell	1,745	$4.19	$7,311.55

Elizabeth Ann Tarka Buying and Selling Activity at Idera Pharmaceuticals

Idera Pharmaceuticals Company Overview

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Today's Range

Now: N/A

50 Day Range

MA: $0.50

$0.17

$7.23

2 Week Range

Now: N/A

Volume

21,870 shs

Average Volume

464,030 shs

Market Capitalization

$450.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

“Forget Tesla, this is Elon’s Next Big Thing”

From InvestorPlace | Ad

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.